<DOC>
	<DOCNO>NCT02660255</DOCNO>
	<brief_summary>This observational , open-label , flexible dose study prospectively longitudinally assess effect Cannabidiol ( CBD ) therapy patient drug-resistant epilepsy Physician Expanded Access Investigational New Drug protocol .</brief_summary>
	<brief_title>Safety Tolerability Cannabidiol Subjects With Drug Resistant Epilepsy</brief_title>
	<detailed_description>This study test Cannabidiol ( CBD ) therapy safe human reduces number and/or severity seizures patient drug resistant epilepsy take addition current anti-epileptic drug ( AEDs ) . To eligible , subject must : - drug-resistant epilepsy - 1 60 year age Subjects may participate 2 year may continue receive drug available , compassionate use terminate drug become approved FDA . The study include : - Baseline , Screening 2 phone call - 12 week drug titration ( 6 visit ) 5 phone call - Approximately 1 year 9 month Treatment period ( 7 visit ) Subjects come visit approximately every two week first three month quarterly remainder study . Subjects ' antiepileptic drug level test monitor drug interaction . Lab assessment ( CBC , CMP , urinalysis ) perform monitor change bone marrow , liver , kidney function ensure safe use . Cannabidiol form 100 mg/ml oral solution . Subjects give CBD take addition current anti-epileptic drug ( AED ) regimen .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>1 . Ages 160 year age . 2 . Patient must least 4 clinically countable seizure per month . They must also prior concomitant videoEEG evidence document diagnosis epilepsy . Seizure history include document history generalize seizure ( drop attack , atonic , tonicclonic and/or myoclonic ) , focal seizure without loss consciousness motor component , focal seizure loss consciousness , focal seizure secondary generalization . 3 . Drug resistant epilepsy define trial least four drug , include one trial combination two concomitant drug , without successful seizure control . Vagal nerve stimulation , RNS deep brain stimulation , ketogenic diet consider equivalent drug trial document evidence drug therapeutic failure . 4 . Between 14 baseline antiepileptic drug time enrollment . Vagus nerve stimulator ( VNS ) , ketogenic diet modify Atkins diet count toward limit contraindicate inclusion . 5 . Subject family sign assent ( capable ) /consent/research authorization able meet study expectation appointment duration study 6 . VNS , use must stable setting minimum 1 month . 7 . If ketogenic diet , must stable ratio minimum 3 month . 8 . Patients caregiver must able consistently maintain seizure diary least 2 month prior enrollment course study period . 9 . Must Nebraska state resident . 1 . Renal , hepatic , pancreatic , hematologic dysfunction evidence : value upper limit normal BUN/creatinine , value twice upper limit normal serum transaminase ( ALT/SGPT , AST/SGOT ) , value twice upper limit normal serum lipase amylase , platelet &lt; 80,000 /mcL , WBC &lt; 3.0 103 /mcL 2 . Less 4 countable ( noncountable seizure include absence myoclonic ) seizures per month 3 . Use cannabisrelated product within last 30 day 4 . Active substance abuse/addiction . 5 . CBD contraindicate pregnancy breastfeeding . Female subject pregnant exclude study . If female subject able become pregnant , give urine pregnancy test entry study . Female subject inform become pregnant take cannabidiol , must agree acceptable method barrier contraception use study include abstinence double barrier method duration treatment . Female subject must tell investigator consult obstetrician maternalfetal specialist become pregnant study . If pregnancy occur , CBD stop clinically appropriate manner . 6 . Allergy CBD cannabinoid . 7 . Unable provide consent ( LAR available ) 8 . Unable comply study visits/requirements . 9 . Use alcohol</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CBD</keyword>
	<keyword>Epidiolex</keyword>
	<keyword>Myoclonic</keyword>
	<keyword>Brain Disease</keyword>
	<keyword>Central Nervous System Disease</keyword>
	<keyword>GWP42003</keyword>
</DOC>